AdvanCell has announced that it has entered into a Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need.
The company has said that the decision reflects AdvanCell’s strategy to build a durable pipeline of differentiated targeted alpha therapies addressing large oncology markets.
The collaboration brings together 48Hour Discovery’s peptide discovery platform and AdvanCell’s 212Pb expertise to rapidly construct and advance a peptide-based radiotherapeutic programme.
Leveraging AdvanCell’s scalable 212Pb platform, which integrates secure isotope supply and modular manufacturing with deep expertise in developing 212Pb radioligand therapies, the programme is designed to enable a rapid, repeatable path into the clinic and support the expansion of AdvanCell’s targeted alpha therapy pipeline.
Under the terms of the agreement, AdvanCell has obtained exclusive worldwide rights for development and commercialisation.
"This collaboration with the 48H Discovery team supports our strategy to build a valuable pipeline, advances a second 212Pb programme into the clinic in 2027 and reinforces our commitment to building a pipeline designed to deliver transformative impact for patients," said Philina Lee, CEO of AdvanCell.
"AdvanCell recently announced compelling clinical results for our lead programme, which gives us confidence that our alpha technology can meaningfully change outcomes for patients in other cancers of high medical need."
"This partnership exemplifies how speed and precision can unlock entirely new therapeutic possibilities," said Rick Finnegan, CEO of 48Hour Discovery.
"By pairing peptides from our novel discovery engine with AdvanCell’s development capabilities, we believe we can bring a truly differentiated therapy to patients who urgently need better options."
This Collaboration and Exclusive Licensing Agreement expands AdvanCell’s existing portfolio of targeted alpha therapies, led by ADVC001, a first-in-class 212Pb-PSMA radioligand therapy. The financial terms of the licensing agreement have not been disclosed.